Alemtuzumab (Campath 1H) in hairy cell leukaemia relapsing after rituximab treatment.
Fietz
Thomas
T
Rieger
Kathrin
K
Schmittel
Alexander
A
Thiel
Eckhard
E
Knauf
Wolfgang
W
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use*; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use; D017338:Cladribine / Q000627:therapeutic use; D003131:Combined Modality Therapy; D019008:Drug Resistance, Neoplasm; D006801:Humans; D007116:Immunization, Passive; D016898:Interferon-alpha / Q000627:therapeutic use; D007943:Leukemia, Hairy Cell / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D012008:Recurrence; D012074:Remission Induction; D000069283:Rituximab; D013156:Splenectomy
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D016898:Interferon-alpha; D000074323:Alemtuzumab; D017338:Cladribine; D000069283:Rituximab